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Available online 29 February 2008Semicarbazide sensitive amine oxidase (SSAO) is a multifunctional enzyme present mainly in adipocytes,
endothelial and smooth muscle cells. It metabolizes primary aliphatic and aromatic amines generating
products able to contribute to cellular oxidative stress. SSAO is expressed in a membrane-bound form and is
also present as a soluble enzyme in plasma. Both isoforms are increased in several pathologies, and the
catalytic products generated by the soluble enzymatic activity can induce cytotoxicity of vascular cells in
culture. We have analyzed whether the transmembrane form of the enzyme is able to produce a cytotoxic
effect through methylamine oxidation. Since cells in culture lose the expression of this enzyme, we used an
SSAO stably transfected smooth muscle cell line. Herein we report that cell treatment with the substrate
methylamine induced a dose and time dependent cytotoxic effect. The tumor suppressor protein p53 played
an important role in the molecular pathway involved in this cell death. Moreover, we also observed the
induction of PUMA-α expression with mitochondrial Bcl-2 family proteins being affected, and ﬁnal effector
caspases being activated.
© 2008 Elsevier B.V. All rights reserved.Keywords:





Smooth muscle cells1. Introduction
Semicarbazide Sensitive Amine Oxidase [E.C.1.4.3.6, oxidoreduc-
tase (deaminating) (copper-containing), SSAO] constitutes a large
family of enzymes which are inhibited by semicarbazide [1,2]. SSAO is
localized in almost all mammalian tissues [3], mainly in fat and in
highly vascularized tissues, where it is associated with both plasma
membranes [4] and cytoplasmic granules [5,6]. SSAO is also present as
a soluble form in blood plasma [2,7], which is thought [8,9] to come
from themembrane-bound form throughmetalloprotease-dependent
shedding [10]. Membrane-bound SSAO shows high activity in smooth
muscle and endothelial cells from blood vessels [1–3]. However, in
those cell types, SSAO seems to be a different molecular entity [4]
exhibiting different regulation and probably different behavior. In fact,
SSAO is considered as a multifunctional protein whose function varies
depending on the tissue where it is expressed [11]. In adipocytes and
smooth muscle cells, SSAO activity stimulates glucose transport,
mimicking the insulin effect [12,13], while in endothelial cells, where
it was also described as vascular adhesion protein-1 (VAP-1) [14], it is
involved in leukocyte trafﬁcking and extravasation under inﬂamma-
tory conditions [14–16].Biologia Molecular, Institut de
noma de Barcelona, (08193)
34 93 5811573.
l rights reserved.The catalytic action of SSAO/VAP-1 requires oxygen and generates
ammonia, hydrogen peroxide (H2O2) and the corresponding aldehyde
as a result of the oxidative deamination of primary aromatic and
aliphatic amines. Aminoacetone andmethylamine (MA) are considered
the physiological SSAO substrates [17], and methylglioxal and for-
maldehyde are their respective metabolites [18]. In this context, the
metabolic end products of the catalytic activity of SSAO have been
considered a potential risk factor for stress-related angiopathy [19,20]
and vascular degeneration. H2O2 is widely implicated in several dis-
eases, as it is a major reactive oxygen species and themain generator of
oxidative stress. Moreover, formaldehyde is a very reactive aliphatic
aldehyde, considered as a powerful inﬂammatory agent [21]. At
different levels, these toxic products potentially induce cell damage
[22–25], activatingmolecular pathways that lead to a programmed cell
death. As a result, plasma SSAO activity throughMAoxidation has been
shown to induce cytotoxicity in endothelial cells [22,26], and apoptosis
in cultured smooth muscle cells [27]. However, the molecular
mechanism by which the SSAO catalytic products could activate
apoptotic processes and induce vascular damage remains unknown.
Our previous studies showed that membrane-bound SSAO was
overexpressed in the cerebrovascular tissue of Alzheimer's Disease
(AD) patients [28] and that soluble SSAO was also found to be
increased in plasma from severe AD patients [29]. In this context, the
aim of the present work was to conﬁrmwhether the overexpression of
membrane-bound SSAO was able to induce vascular cell death
through its own catalytic action on MA as substrate, and to elucidate
the molecular pathway activated in such vascular damage.
1086 M. Solé et al. / Biochimica et Biophysica Acta 1783 (2008) 1085–1094In this studywe report that amethylamine (MA) treatmentof SSAO/
VAP-1 stable transfected smooth muscle cell line (A7r5) [30] induces
an apoptotic cell death mediated by the SSAO substrate oxidation
products. The study of different molecular pathways involved in the
process revealed the key role of the tumor suppression protein p53
through the mitochondrial pathway in this mediated cell death.
2. Materials and methods
2.1. Cell culture and treatments
A7r5WT rat aortic smoothmuscle cell linewas obtained from the ECACC (European
Collection of Cell Cultures, Wiltshire, UK). A7r5 hSSAO/VAP-1 cell lines were obtained
by means of stable transfection of A7r5 WT cell line with SSAO/VAP-1 human cDNA
[30], and different positive clones were ampliﬁed as different cell lines to use in this
work. Moreover, VAP-1/SSAO stable expression in the A7r5 hSSAO/VAP-1 cell line was
periodically conﬁrmed by Western Blot using the antibodies cited in Protein detection
by Western Blot analyses (data not shown). All cell lines were grown in high glucose
(4.5 mg/l) DMEM (Sigma-Aldrich, St. Louis, Mo., USA) supplemented with 10% (v/v) FBS
(Invitrogen, Grand Island, NY, USA), 2 mM L-glutamine (Invitrogen, Grand Island, NY,
USA), 1000 U/ml penicillin and 1000 U/ml streptomycin (PAN Biotech GmbH,
Aidenbach, Germany) and maintained at 37 °C in a humidiﬁed atmosphere containing
5% CO2. Geneticin (G418, 100 μg/ml, Invitrogen (Grand Island, NY, USA)) was added to
the culture medium to ensure SSAO/VAP-1 DNA maintenance. For experiments, cells
were seeded at 40000 cells/ml, grown for 24 h and starved with DMEM containing 0.2%
(v/v) FBS for 1 h before treatment. For treatments, semicarbazide was coincubated with
MA; catalase was added 30 min before MA, H2O2 or FA addition; formaldehyde
dehydrogenase inhibitors were added 30 min before FA addition and piﬁthrin-α was
added 1 h before MA addition. Semicarbazide, MA, H2O2, FA, catalase, piﬁthrin-α and
formaldehyde dehydrogenase inhibitors (4-methylpyrazole, 1-bromoheptane, cyana-
mide, chloral hydrate) were purchased from Sigma-Aldrich (St. Louis, Mo., USA).
2.2. Cell viability assays
Cell viability was determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) reduction assay or by LIVE/DEAD Viability/Cytotoxicity KitFig. 1.MA oxidation by the transmembrane form of hSSAO/VAP-1 induces cytotoxicity in hSSA
(2) cells were treated during 1, 2 or 3 days with methylamine (MA) 1 or 3 mM, semicarbazide
are the mean±SEM of three independent experiments performed in triplicate. (⁎) pb0.01 vs
Keuls Multiple Comparison test. (B) Cells were treated for 2 days with MA 3 mM (3 and 7), S
ﬂuorescence Viability/Cytotoxicity Kit which dyes live cells in green and dead cells in red.
triplicate for three separate experiments.(Molecular Probes-Invitrogen (Grand Island, NY, USA)). For MTT estimations, cells
were plated in 24-well plates, and MTT solution (0.5 mg/ml, ﬁnal concentration) was
added to cells 90 min before the end of the treatments; after these 90 min of incubation
at 37 °C the medium was replaced with dimethyl sulfoxide to dissolve the formazan
blue precipitate formed, which was quantiﬁed at 560 and 620 nm in amicroplate reader
(Labsystems multiskan RC) [31]. For LIVE/DEAD Viability/Cytotoxicity Kit cells were
plated in 24-well plates and after treatments, 0.2 μM of Calcein/AM and ethidium
homodimer-1 (EthD-1) was added with fresh medium. Cells were incubated for 15 min
at 37 °C and then examined using an inversed microscope Nikon Eclipse TE 2000-E and
a Hamamatsu C-4742-80-12AG camera. Calcein/AM is adsorbed by living cells and
becomes a substrate for cytosolic esterases, which convert it into a green ﬂuorescent
product (Excitation 495 nm/Emission 530 nm), whereas EthD-1 is only able to enter
cells with compromised cell membrane integrity, and becomes red ﬂuorescent after its
attachment to nucleic acids (Excitation 495 nm/Emission 635 nm).
2.3. Protein detection by Western Blot analysis
Cells were plated in 60 mm dishes, and after treatments, cells were washed in cold
PBS and lysed in a buffer containing 1% Triton X-100, 10 mM EDTA, 50 mM Tris–HCl pH
7.5 and protease inhibitors (protease inhibitor cocktail, Sigma-Aldrich, Mo., USA). The
lysates were incubated 10min on ice, sonicated and centrifuged at 8000 ×g for 15min at
4 °C. Protein concentration was determined by the Bradford method. An equal amount
of protein (20 μg/lane) was separated by SDS-polyacrylamide gel electrophoresis using
the Bio-Rad Mini-PROTEAN 3 system, and transferred onto nitrocellulose membranes.
Membranes were blocked for 1 h with TBS-Tween buffer (66 mM Tris, 41.44 mM NaCl,
0.1% Tween 20) containing 5% (w/v) non fat dry milk, and incubated overnight at 4 °C
with the corresponding primary antibodies diluted 1:1000 in the blocking buffer. The
primary antibodies used were anti-cleaved caspase 3, anti-cleaved caspase 9, anti-Bax,
anti PUMA and anti-phospho p53 antibodies from Cell Signaling (Beverly, MA, USA),
anti-Bcl-2 from BD Biosciences Pharmingen (San Diego, CA, USA), anti-β-actin from
Sigma-Aldrich (St. Louis, Mo., USA), anti-p53 from Abcam (Cambridge, UK), anti-SSAO
E-19 and anti-SSAO H-43 from Santa Cruz Biotechnology (Heidelberg, Germany). After
incubation with the appropriate secondary antibodies (HRP anti-rabbit igG from BD
Biosciences Pharmingen or HRP anti-mouse IgG from Dako Cytomation (Glostrup,
Denmark)) in the blocking buffer for 1 h, blots were developed using ECL®
chemoluminiscent detection reagent and High Performance Chemiluminiescence
Films from Amersham Pharmacia Biotech (GE Healthcare, UK). Semi-quantitativeO/VAP-1 cells, shown as two different cell viability assays. (A)WT (1) and hSSAO/VAP-1
(Sc) 1 mM, or both, and cell viability bymeasuring MTT reductionwas determined. Data
control, (#) pb0.01 vs Ma+Sc by a one-way ANOVA test and the addition of Newman–
c 1 mM (2 and 6), both (4 and 8) or none (1 and 5). Cell viability was assessed with the
Scale bar=100 μm. Representative images were taken by each treatment performed in
Fig. 2. Formaldehyde is the main contributor of the cytotoxicity induced by
methylamine's oxidation. hSSAO/VAP-1 cells were treated for 2 days with MA
(3 mM), hydrogen peroxide (H2O2) (1 mM) or formaldehyde (FA) (1 mM) alone or
with a 30 min pretreatment of catalase (Cat) (50 U/ml) as well. Cell viability was
determined by MTT reduction method. Data are the mean±SEM of three independent
experiments performed in triplicate. (⁎⁎⁎) pb0.001, (⁎) pb0.05, (n.s.) pN0.05 by a one-
way ANOVA test and the addition of Newman–Keuls Multiple Comparison Test.
1087M. Solé et al. / Biochimica et Biophysica Acta 1783 (2008) 1085–1094analysis of Western Blots was performed by densitometry, using the Image J 1.34 s
software (National Institutes of Health, USA), and protein levels were corrected for
corresponding loading control.Fig. 3. Intracellular FA dehydrogenases do not modify FA induced toxicity. hSSAO/VAP-1
dehydrogenase inhibitors alone or plus FA (0.5 mM). A 30 min pretreatment was done with
Inhibitors used were: (A) 4-methylpyrazole (4-MP), as alcohol dehydrogenase 1 (ADH 1) in
(ADH 3) inhibitor; (C) cyanamide (Cyan), as aldehyde dehydrogenase 2 (ALDH 2) inhibitor; a
are the mean±SEM of three independent experiments performed in triplicate.2.4. Caspase 3/7 activity determination
Caspase 3/7 activity was measured by EnzChek® Caspase-3/7 Assay Kit (Molecular
Probes-Invitrogen (Grand Island, NY, USA)). Cells were seeded in 100 mm dishes and
after treatments, samples were lysed according to the kit manufacturer's instructions.
The Caspase 3/7 activity was determined by the amount of AMC released (Excitation
342 mn/Emission 441 nm), which was measured using the ﬂuorescent microplate
reader Synergy HT and date analysis software KC4 ™ (Bio-Tek® Instruments Inc.
Winooski, USA). AMC concentration generated by each sample was then corrected by
the corresponding protein concentration. Data is expressed as fold caspase 3/7 activity
relative to untreated samples.
2.5. Statistics
Results are given as means±SEM of independent experiments. Statistical analysis
was done by one-way ANOVA and further Newman–Keuls Multiple Comparison Test. A
p value of less than 0.05 was considered to be statistically signiﬁcant. Statistical analysis
and graphic representations were obtained using Graph-Pad Prism 3.0 program.
3. Results
3.1. MA oxidation induces cytotoxicity in A7r5 hSSAO/VAP-1 stably
transfected cells
SSAO/VAP-1 expression has been shown to be lost in cultured cells
[13,22]. In this work, a transformed smooth muscle cell line (A7r5
hSSAO/VAP-1), which expresses the transmembranal human SSAO/
VAP-1 protein in a stable manner [30], was used to study the effect of
methylamine (MA) oxidation by this enzymatic form in cell culture.
Untransfected cells (A7r5 WT) were used as the negative control for
treatments.cells were treated for 18 h with increasing concentrations of different formaldehyde
inhibitors before FA addition. Cell viability is expressed as MTT reduction percentages.
hibitor; (B) 1-bromoheptane (1-BR), as GSH-dependent formaldehyde dehydrogenase
nd (D) chloral hydrate (Chl Hyd), as aldehyde dehydrogenase 2 (ALDH 2) inhibitor. Data
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metabolism, both cells were treated with different concentrations of this
substrate. WT cells, which do not express SSAO/VAP-1 protein [30], and
hSSAO/VAP-1 cellswere treatedwithMA(1and3mM)during1 to3days,
and semicarbazide (Sc)was used as SSAO inhibitor. Fig.1.A shows the cell
viability results obtained after the corresponding treatments measured
by the MTT reduction assay, as previously described in Materials and
methods. In WT cells, neither MA nor Sc had any effect on cell viability
(Fig. 1.A.1). However, a dose and time-dependent cytotoxic response was
observed in hSSAO/VAP-1 cells after MA treatment (Fig. 1.A.2), with a
maximum 40% decrease in MTT reduction after 72 h treatment with
1 mM MA and an 85% decrease in MTT reduction after 72 h treatment
with 3 mM MA. The total recovery of the cell viability in hSSAO/VAP-1
cells afterMAand Sc cotreatment, conﬁrmed that themetabolic products
obtained from MA oxidation by transmembranal SSAO/VAP-1 mediated
the cytotoxic process. Fig. 1.B shows the effect of 3 mM MA, 1 mM Sc or
their cotreatment in WT and hSSAO/VAP-1 cells using the ﬂuorescence
Viability/Cytotoxicity Kit, which allows live and dead cells to be stained
simultaneously in green and red ﬂuorescence, respectively. After 48 h
treatment with 1 mM Sc (Fig. 1.B.2), 3 mMMA (Fig. 1.B.3), 1 mM Sc plus
3 mM MA (Fig. 1.B.4) or untreated cells (Fig. 1.B.1), no changes were
observed in WT cells, which showed a morphological integrity and
emitted mainly green ﬂuorescence. Although hSSAO/VAP-1 cells did not
show any effect by 1 mM Sc treatment (Fig. 1.B.6), 3 mM MA treatment
induced clear cell shrinkage and shedding, allowing EthD-1 to enter.Fig. 4.Methylamine oxidation by transmembrane hSSAO/VAP-1 induces caspase 3 activation.
of MA 3 mM treatment in WT and hSSAO/VAP-1 cells. Values of densitometric analysis of th
expressed in arbitrary units versus untreated cells (NT) and represent the mean±SEM of th
3 mM treatment in hSSAO/VAP-1 cells. (C) Caspase 3 activity levels after 32 h treatment of
ﬂuorescence units versus untreated cells (0 h or NT) and represent the mean±SEM of three
test and the addition of Newman–Keuls Multiple Comparison Test.Moreover, cotreatment of 3 mM MA and 1 mM Sc prevented the cell
degeneration observed with MA alone, indicating that SSAO activity was
the only cause of the cell damage observed.
3.2. FA is the main contributor to the cytotoxicity mediated by MA
oxidation in hSSAO/VAP-1 cells
Since MA oxidation induced a clear cytotoxic effect when it was
incubated with those cells that expressed transmembrane SSAO, we
next studied the contribution of eachMAoxidationproduct to the toxic
process observed. Both cell types were treated with increasing
concentrations of the ﬁnal products: NH4, H2O2 or Formaldehyde
(FA), from 0.1 to 1 mM during 24 h (data not shown) and cell viability
results indicated similar behavior for both cell types, expressing or not
SSAO/VAP-1. Whereas NH4 did not produce any effect in any of the
assayed concentrations (0.1–1 mM), H2O2 produced a decrease of 60%
inMTT reduction only in themaximum concentration assayed (1mM).
FA induced 40% cell viability loss at low concentration (0.1 mM), and
reached an 80–90% of cell death at 0.25mM, indicating that FAwas the
most toxic metabolic product in the conditions assayed.
To ensure that FA was the main cause of the toxicity observed,
hSSAO/VAP-1 cells were treated for 2 days with 3 mMMA,1 mMH2O2
and 1 mM FA alone or with 50 U/ml of catalase, in order to determine
the H2O2 contribution to the overall cytotoxic effect of MA oxidation
(Fig. 2). Although catalase pretreatment succeeded in recovering the(A) Representative immunoblot of 17 KDa caspase 3 active fragment after different times
e 17 KDa band corresponding to active caspase 3 in MA treated hSSAO/VAP-1 cells are
ree independent experiments. (B) Caspase 3 activity levels after different times of MA
hSSAO/VAP-1 cells with MA 3 mM, Sc 1 mM or both. Data in B and C are expressed in
independent experiments. (⁎⁎⁎) pb0.001, (⁎⁎) pb0.01, (⁎) pb0.05 by a one-way ANOVA
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protect cells after MA treatment. Moreover, catalase alone did not
produce any change in hSSAO/VAP-1 cell viability by itself andwas not
able to recover the cytotoxicity after FA treatment either. Surprisingly,
catalase treatment enhanced the cell death caused by MA oxidation.
In order to elucidate whether FA exerted its cytotoxic effect inside or
outside the cells, they were preincubated for 30 min with different
aldehyde dehydrogenase inhibitors before 18 h FA treatment (Fig. 3).
Increasing concentrations of intracellular dehydrogenase inhibitors
were used alone or plus 0.5 mM FA. The inhibitors used were
4-Methylpyrazole (4-MP) (Fig. 3.A), as an alcohol dehydrogenase 1 (ADH
1) inhibitor; 1-Bromoheptane (1-BR) (Fig. 3.B), as a GSH-dependent
formaldehyde dehydrogenase (ADH 3) inhibitor and Cyanamide (Cyan)
(Fig. 3.C) and chloral hydrate (Chl Hyd) (Fig. 3.D) as aldehyde
dehydrogenase 2 (ALDH 2) inhibitors. All of them were assayed in a
range from 0 to 500 μM. If FA toxic effect had been triggered inside the
cells, the expected results would show an increase of FA cytotoxicity at
higher dehydrogenase inhibitor concentrations. However, our results
showed no differences in cell viability loss between FA alone or when it
was incubated in the presence of different concentrations of the
dehydrogenase inhibitors assayed: 4-MP (Fig. 3.A), 1-BR (Fig. 3.B),Fig. 5. Methylamine oxidation by transmembrane hSSAO/VAP-1 activates the mitochon
(A) Representative immunoblot of 37 KDa caspase 9 active fragment after different times of M
and Bcl-2 protein levels after different times of MA 3 mM treatment in WT and hSSAO/VAP-
cells. Data are expressed in densitometric units versus untreated cells (NT) and represent th
(⁎) pb0.05 by a one-way ANOVA test and the addition of Newman–Keuls Multiple CompariCyan (Fig. 3.C) or Chl Hyd (Fig. 3.D). In the case of cyanamide (Fig. 3.C), a
loss of cell viability was observed in correlation with increasing
cyanamide concentrations. This effect was also observed with cyana-
mide alone, indicating that the inhibitor was toxic by itself. So, these
results suggested that FA toxicity was not produced inside the cells.
3.3. MA oxidation by membrane-bound hSSAO/VAP-1 induces an
apoptotic cell death
Caspase 3 is one of the main executer caspases in the apoptotic
process, and its cleavage is one of the classic apoptotic features. To
evaluate whether MA oxidation products were leading to an apoptotic
cell death, caspase 3 cleavage was assayed by Western Blot and its
activity by using EnzChek®Caspase-3/7AssayKit (Molecular Probes) in
hSSAO/VAP-1 cells treated with MA. Fig. 4.A shows a representative
immunoblot of caspase 3 cleavage. The 17-KDa active fragment of
caspase 3 appeared after 24 h of MA treatment in hSSAO/VAP-1 cells,
but not inWTcells, conﬁrming the previous cell viability results (Fig.1)
and indicating that MA by itself does not induce apoptotic cell damage.
The 17 KDa active fragment of caspase 3 appeared to increase
signiﬁcantly from 24 to 55 h of treatment.drial apoptotic pathway including caspase 9 cleavage and Bax/Bcl-2 ratio increase.
A 3mM treatment inWTand hSSAO/VAP-1 cells. (B) Representative immunoblots of Bax
1 cells. (C) Bax/Bcl-2 ratio after different times of MA 3 mM treatment in hSSAO/VAP-1
e mean±SEM of three independent experiments. β-actin was used as loading control.
son Test.
1090 M. Solé et al. / Biochimica et Biophysica Acta 1783 (2008) 1085–1094When caspase 3 activity was measured using the EnzChek ®
Caspase-3/7 Assay Kit, results showed that 24 hMA treatment induced
a two fold increase in caspase 3 activity versus control (Fig. 4B). The
maximum rate was reached at 32 h treatment, and after that, it began
to decline. A cotreatment of MA with semicarbazide at the maximum
activation point blocked this caspase 3 activity and conﬁrmed that MA
oxidation was the responsible of such effect (Fig. 4.C).
After the caspase 3 cleavage and activation was conﬁrmed, the
possibility that caspase 9was the responsible of activating caspase 3was
assessed. As shown in Fig. 5.A, caspase 9 cleavage was determined by
Western Blot analysis after 3mMMA treatment at different time points.
The presence of the 37 kDa caspase 9 fragment increased in a time-
dependentmanner afterMA treatment in hSSAO/VAP-1 cells, reaching a
maximum cleavage at 55 h. On the other hand, no cleaved form was
detected under the same conditions inWTcells. Caspase 3 and caspase 9
cleavages showed a similar timing pattern, so is reasonable to suggest
that caspase 9 could act as one of the caspase 3 activator molecules.
3.4. Cytotoxicity mediated by MA oxidation activates the mitochondrial
apoptotic pathway
Caspase 9 is involved in two important apoptotic signaling
pathways: mitochondrial (or intrinsic) pathway [32] and reticular
stress (ER) pathway [33,34]. To investigate their involvement in the
caspase 9 activation process, some of the main characteristic protein
markers of these two pathways were analyzed by Western Blot.
The GRP78 chaperone plays a crucial role in the ER misfolding
protein process [35]. Its protein levels were determined by means of
Western Blot, but results did not show signiﬁcant differences after MA
treatment in hSSAO/VAP-1 orWTcells (data not shown), so the ER stress
apoptotic pathway was rejected as the cause of caspase 9 activation.
The other main apoptotic pathway which requires caspase 9
cleavage is the intrinsic or mitochondrial pathway [36,37]. The mito-
chondrial apoptotic pathway is regulated by the ratio of anti to pro-Fig. 6. Methylamine oxidation induces p53 phosphorylation of serine-15 residue and PUMA
(serine 15) and total p53 after different time treatments of WT and hSSAO/VAP-1 cells wit
treatment without changes of total p53 protein levels. Data of phospho-p53 induction in
(B) Representative immunoblots of PUMA (isoforms α and β) after MA treatment. PUMA-α le
48 h; in contrast, PUMA-β levels decreased in hSSAO/VAP-1 cells at 55 and 72 h, but they d
expressed as densitometric units versus non-treated cells (NT). β-actin was used as loa
independent experiments. (⁎⁎⁎) pb0.001, (⁎⁎) pb0.01, (⁎) pb0.05 by a one-way ANOVA testapoptotic molecules, which includes the Bcl-2 family [38]. Representa-
tive Western Blots of Bax and Bcl-2 protein levels are shown in Fig. 5.B.
MA treatment inWTcells did notmodify the pro-apoptotic protein Bax.
Comparably, Bax protein levels were not affected by MA oxidation
products generated in hSSAO/VAP-1 cells afterMA treatment. However,
in hSSAO/VAP-1 cells only, the anti-apoptotic protein Bcl-2 showed
a signiﬁcant reduction in protein levels after 48 h of MA treatment.
Fig. 5.C shows the Bax/Bcl-2 ratio in those cells, conﬁrming its alteration
after 48 h of MA treatment, and indicating the probably involvement of
the mitochondrial pathway in the cell death studied.
3.5. p53 phosphorylation and PUMA-alpha are increased in hSSAO/VAP-1
cell death under MA oxidation conditions
P53 is related to the mitochondrial apoptotic pathway activation
through different cell damaging insults [39]. To assess whether p53
had any role inMA oxidationmediated toxicity, its phosphorylation on
serine 15 was determined, since this residue has been described as an
apoptosis-related phosphorylation site [40]. Fig. 6.A shows represen-
tative immunoblots of MA treated WT and hSSAO/VAP-1 cells for
phospho-p53 in serine 15 and total p53 protein. No p53 phosphoryla-
tion in ser-15 residue was observed in WT cells. On the contrary, blots
corresponding to hSSAO/VAP-1 cells showed an increase of phospho-
p53 in ser-15, which began at 12 h and reached amaximum rate at 36–
48 h of MA treatment, decreasing after this point. Even so, none of the
blots showed changes in total p53 protein levels, indicating the
presence of phosphorylated protein without de novo synthesis.
PUMA expression induced by p53 transcriptional activity has been
demonstrated to be required for p53-mediated cell death through the
mitochondrial pathway under numerous p53-dependent apoptotic
stimuli [41–43]. In our study, PUMA α and β protein levels were
determined by Western Blot in MA treated cells (Fig. 6.B). In WT cells,
neither PUMA α, nor PUMA β protein levels changed during MA
treatment:whereas PUMAαwas almost undetectable, PUMAβ isoform-α expression in hSSAO/VAP-1 cells. (A) Representative immunoblots of phospho-p53
h MA 3 mM. P53 phosphorylation is increased in hSSAO/VAP-1 cells after 12 h of MA
hSSAO/VAP-1 cells are expressed in densitometric units versus non-treated cells (NT).
vels increased in hSSAO/VAP-1 cells after 12 h of treatment, and were maintained until
id not change in WT cells. Quantiﬁcation of PUMA-α induction in hSSAO/VAP-1 cells is
ding control. In both cases, densitometric values represent the mean±SEM of three
and the addition of Newman–Keuls Multiple Comparison Test.
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PUMA α at 36–48 h was observed in MA treated hSSAO/VAP-1 cells at
24 h of treatment, whichwasmaintained until 48 h. On the other hand,
PUMAβ expressionwasnot increasedafterMAtreatment in transfected
cells, showing slower protein levels at longer time treatments (55 and
72 h). These results suggested a possible involvement of p53, through
PUMA α expression induction, on the mitochondrial deregulation
observed in MA oxidation mediated toxicity.
3.6. p53 activity mediates hSSAO/VAP-1 cell death under MA oxidation
conditions
To test whether p53 activation was mediating the apoptotic cell
death through a transcription-dependentmechanism, piﬁthrin-α [44],
a p53 transcriptional activity inhibitor, was coincubated with MA.
Different concentrations of piﬁthrin α (1, 5 and 10 μM) were added 1 hFig. 7. p53 transcriptional activity inhibition with piﬁthrin-α reverts hSSAO/VAP-1 cell death
VAP-1 cells (B) were treated with MA 3mM, Sc 1 mM or/and piﬁthrin α (1, 5 or 10 μM) during
dependent cell viability recovery of MA treated hSSAO/VAP-1 cells. Piﬁthrin-α was not sig
determined by MTT reduction method. Data are the mean±SEM of three independent exper
one-way ANOVA test and the addition of Newman–Keuls Multiple Comparison Test, where
with MA 3 mM during different times with or without piﬁthrin 5 μM. Representative immun
VAP-1 cells represents the mean±SEM of three independent experiments. Data are expresse
(⁎⁎) pb0.01 vs non-treated cells; (###) pb0.001 and (##) pb0.01 vs MA 3 mM, by a one-wbefore the 48 h MA treatment (Fig. 7). Cell viability determinations
showed that piﬁthrin-α produced a dose-dependent cell viability
recovery of MA induced toxicity in hSSAO/VAP-1 cells obtaining a
complete cytoprotection with 10 μM piﬁthrin-α (Fig. 7.B). This dose-
dependent recovery was observed also at 72 h treatment in hSSAO/
VAP-1 cells (data not shown). WT cells did not show any cytotoxicity
with MA treatment, and piﬁthrin-α treatment produced a slight
cytotoxicity on these cells (Fig. 7.A). The total cell death recovery after
piﬁthrin α pretreatment evidenced the role of p53 in the early and
advanced SSAO mediated apoptotic process.
Finally, to ensure that mitochondrial alterations, as Bax/Bcl-2 ratio
increase, were induced by the activation of p53 pathway, hSSAO/VAP-
1 cells were treated with MA at different time points, with or without
piﬁthrin-α, and Bax and Bcl-2 protein expression was analyzed by
Western Blot (Fig. 7.C). Treatment of hSSAO/VAP-1 cells with piﬁthrin-
α blocked Bcl-2 decrease, and did not change Bax protein levels. Theseand Bax/Bcl-2 ratio increase induced by MA oxidation products. WT cells (A), or hSSAO/
48 h. Piﬁthrin-αwas added 1 h before MA and Sc treatment. Piﬁthrin-α produced dose-
niﬁcantly toxic by itself at assayed concentrations (data not shown). Cell viability was
iments performed in triplicate. (⁎⁎⁎) pb0.001, (⁎⁎) pb0.01, (⁎) pb0.05, (n.s.) pN0.05 by a
all columns were compared with MA 3 mM values. (C) hSSAO/VAP-1 cells were treated
oblots for Bax and Bcl-2 proteins are shown. Bax/Bcl-2 ratio after treatments in hSSAO/
d in densitometric units versus untreated cells (0h). β-actin was used as loading control.
ay ANOVA test and the addition of Newman–Keuls Multiple Comparison Test.
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conﬁrming that the activation of the p53-dependent pathway was
directly involved in the apoptotic process induced by MA oxidation.
4. Discussion
SSAO activity is altered in several pathological conditions. MA and
plasma SSAO are increased in patients suffering from diabetes type I
and II [45,46], but increased plasmatic SSAO activity has been found
also in patients afﬂicted by many other pathologies related with
vascular system and/or inﬂammatory conditions [46–49]. Increased
SSAO activity has also been related to diseases affecting the nervous
system, as Alzheimer's disease (AD) [50] or multiple sclerosis [51]. In
this context, we have previously reported that circulating SSAO
activity is increased in plasma from severe AD patients [29], and that
membrane-bound SSAO is overexpressed in the cerebrovascular tissue
of AD and CADASIL (Cerebral Autosomal Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy) patients, with the
subsequent perturbation of the brain vasculature [28].
Increased SSAO activity can lead to a rise in its metabolic prod-
ucts, such as methylglioxal, formaldehyde and hydrogen peroxide,
which are involved inproducing covalent cross-linkswith proteins and
DNA [24,52,53], generating advanced glycation end products (AGEs)
[54,55], and inducing oxidative stress by producing free radicals
[23,56]. In fact, soluble SSAO mediated amine oxidation in endothelial
[22,57] and smoothmuscle cells in culture [27,58,59] have both shown
a cytotoxic effect. Given that the membrane-bound enzymatic form
has also been shown to be overexpressed in pathologic situations, we
have studied whether the metabolism of the cellular enzyme is a
potential source of vascular cell damage. Although tissues show
elevated SSAO levels, cells in culture stop expressing this protein
[13,22]. In order to study the metabolism by membrane-bound SSAO,
we have used a transformed smooth muscle cell line which stably
expresses the human SSAO protein [30].
In this study, we show that MA at both 1 and 3 mM produces a
cytotoxic effect only in cells expressing SSAO (hSSAO/VAP-1 cells), but
not in untransfected (WT) cells. Since our model is based on acute
treatments of cultured cells, the MA levels used in this work are higher
than those reported in physiological conditions for human plasma [60],
even so, this MA concentration range has been widely used in many
other cell culture studies [13,22,58]. The SSAO activity levels obtained
from the transfected cell line are similar to those observed in smooth
muscle tissue [30], suggesting that acute exposures to SSAO substrates
could produce a chronic vascular damage by toxic substances
accumulation. In fact, cytotoxic effects appear after 1–2 days cell
treatments, whereas other studies have not observed this toxic effect
after short termexposures (hours) toMA [13].Moreover, several studies
have reported increased vascular damage in animals treated with the
SSAO substrates aminoacetone or methylamine [55,61]. Vascular
complications like AGE formation, hypertension, atherosclerosis,
glomerulosclerosis or retinopathy also have been observed in trans-
genicmice overexpressing human VAP-1 [61,62]. Moreover, an increase
of reactive aldehydes generated by SSAO and other amine oxidases has
been found in neurodegenerative diseases, and may contribute to the
development and progression of these disorders [63].
Our results show that MA plus catalase cotreatment does not
recover cell death induced by MA oxidation, conﬁrming the principal
role of formaldehyde in the toxicity process, in agreement with
previous reports [22,27]. On the contrary, this cotreatment increased
the cytotoxicity. This effect could be explained by the fact that H2O2
removal may shift the MA oxidation reaction in the direction of
product generation, which would increase the formaldehyde concen-
tration, and thus raising the cytotoxic effect. Alternatively, we cannot
rule out that subtoxic H2O2 doses may induce pro-survival molecular
pathway activation, such as the PKB/AKT pathway [64], which might
induce more resistance to the toxic insults.The mechanism by which formaldehyde induces a cytotoxic effect
in our in vitro system remains unknown. Teng et al. [65] reported that
pretreating hepatocytes with different intracellular formaldehyde
dehydrogenase inhibitors before treating with formaldehyde
enhanced its toxicity, showing that the aldehyde was permeable to
the cell membrane and acted inside the cytosol. However, treatments
with formaldehyde dehydrogenase inhibitors do not enhance for-
maldehyde toxicity in our model. These results suggest that formalde-
hydemayact fromoutside the cellmembrane, since it is a very reactive
molecule able to induce extracellular protein crosslinkings, thus
activating intracellular molecular pathways. Possible recognition of
formaldehyde by extracellular receptors could not be ruled out. Even
so, it should be considered that formaldehyde detoxiﬁcation enzyme
systems are different between cell types, and this fact could explain the
different results obtained with the formaldehyde dehydrogenase
pretreatments.
Cytotoxic damage induced in smooth muscle cells by MA oxidation
products leads to the activation of caspase 3, one of themain apoptosis
executers, as was shown previously by soluble SSAO activity [27]. The
study of the signaling pathways that could lead to this apoptotic fate in
our system reveals that the MA treatment of hSSAO/VAP-1 cells does
not modify the constitutive expression of pro-apoptotic protein Bax,
but it signiﬁcantly decreases the anti-apoptotic protein Bcl-2 levels,
leading to deregulation of the pro/anti-apoptotic protein balance.
Alterations of the ratio between these proteins, such as Bax/Bcl-2, are
considered determinant events for apoptosis induction by mitochon-
drial pathway [38]. In addition, a p53 phosphorylation has been
observed after same treatment in transfected cells. Supporting these
results, it has been previously described that p53 activity can down-
regulate the expression of Bcl-2 [66]. Moreover, although Bax is a
transcriptional target of p53 activity [67], its induction has been
shown not to be necessary for p53-dependent apoptosis, since p53 is
able to induce Bax oligomerization and this promotes mitochondrial
outer membrane permeabilization (MOMP) [68,69]. Another evidence
that these mitochondrial alterations are key events in the apoptotic
progression is the activation of caspase 9 in MA treated transfected
cells. Its activation takes place after the mitochondrial factors release
[70]. Although caspase 9 is also activated in late stages of reticular
stress apoptotic pathway, this signaling cascade was rejected to take
part in our model since protein levels of GRP78, a key chaperone in the
Unfolded Protein Response (UPR) [71], are not altered after MA
treatment.
p53 is activated under conditions such as oncogene expression,
DNA damage or other sources of cellular stress [72]. In response to
these cell insults, phosphorylation or other posttranslational mod-
iﬁcations can stabilize p53 and let it act through transcription-
dependent or independent mechanisms of apoptosis (reviewed by
[73] and [39]). Serine 15 phosphorylation seems to be the p53
stabilization mechanism in SSAO mediated cytotoxicity in smooth
muscle cells. After this, p53 could have direct effects on the
mitochondria decreasing Bcl-2 levels, or activate the transcription of
its target genes. As well as BAX, the pro-apoptotic mitochondria-
related genes PUMA, NOXA and BID are also induced by p53
transcriptional activity [41,74,75]. The total recovery of cell death
with piﬁthrin-α treatment suggests that, although p53 is able to
induce apoptosis without transcription or protein synthesis in certain
conditions [76], this activity is essential to the cytotoxicity mediated
by SSAO. Moreover, the prevention of the Bax/Bcl-2 increase after
piﬁthrin-α pretreatment in MA treated cells suggested the involve-
ment of this single apoptotic pathway in mediating this cell death.
PUMA could be a candidate to mediate such activity, since PUMA-α is
increased after MA treatment in hSSAO/VAP-1 cells. Although PUMA
has several isoforms with different regulations [41], α form has been
shown to be induced in certain types of p53-dependent apoptosis, in
contrast to PUMA-β [77]. PUMA is able to bind to anti-apoptotic
proteins like Bcl-2 or Bcl-XL through its BH3 domain, antagonizing its
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Taking all, the increase of the PUMA-α isoform observed in this work
suggests that it could be participating in this cell death pathway.
However, since there are multiple p53-inducible genes, other proteins
might be involved in the process.
In summary, the protein analyses performed in this work demon-
strate that the mitochondrial pathway is involved in cell death induced
by MA oxidation. In the signaling sequence, p53 activation induced by
MA oxidation products might lead to decrease Bcl-2 levels, thus
allowing Bax oligomerization and inducing mitochondrial permeabili-
zation, which in turn activates caspase 9 and caspase 3. This pathway
could be reinforced by p53 mediated PUMA expression, which may
contribute to the over-availability of pro-apoptotic proteins by anti-
apoptotic proteins sequestration. Additionally, the toxicity recovery in
the presence of piﬁthrin-α, a p53 transcriptional activity inhibitor
extensively used in blocking p53 pathway [44,80,81], suggests a
principal role for p53 in mediating this cell death.
Our study supports the idea that in conditions in which
membrane-bound SSAO is overexpressed, its chronically elevated
activity could lead to vascular cell damage through its catalytic
products. Recently, several studies have been developed new SSAO
inhibitor molecules to target potential treatments for inﬂammatory
diseases [82–84]. As far as this is concerned, our ﬁndings contribute to
the idea that SSAO inhibition would be useful in blocking the cell
damage source induced by SSAO activity in such pathologies.
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